Bedford Theresa, Kisaalita Nkaku, Haycock Nathaniel R, Mullins C Daniel, Wright Thelma, Curatolo Michele, Hamlin Lynette, Colloca Luana
711 Human Performance Wing, En Route Care, Wright Patterson Air Force Base, OH, United States.
Mental Health Service Line, Orlando Veterans Affairs Healthcare System, Orlando, FL, United States.
Front Psychiatry. 2022 Mar 24;13:820357. doi: 10.3389/fpsyt.2022.820357. eCollection 2022.
Standard opioid tapers tend to be associated with increased patient anxiety and higher pain ratings. Pre-authorized concealed opioid reductions may minimize expectations such as fear of increased pain due to the reduction of opioids and, prolong analgesic benefits in experimental settings. We recently observed that patients and clinicians are open to concealed opioid tapering. However, little is known about the "why" behind their attitudes. Based on this lack of data, we analyzed qualitative responses to survey questions on patients' and clinicians' acceptance of a concealed opioid reduction for chronic pain. Seventy-four patients with a history of high dose opioid therapy and 49 clinicians completed a web-based questionnaire with open-ended questions examining responses to two hypothetical clinical trials comparing a concealed opioid reduction pre-authorized by patients vs. standard tapering. We used content analysis based on qualitative descriptive methodology to analyze comments from the patients and clinicians. Five themes were identified: informed consent; anxiety; safety; support; and ignorance is bliss, or not. These themes highlight the overall positive attitudes toward concealed opioid tapers. Our findings reinforce the importance of patient-centered care and are expected to inform the design of clinical trials from both the patient and clinician perspective. This qualitative study presents patients' and clinicians' attitudes toward hypothetical scenarios for a trial of pre-authorized reduction of opioids. The findings indicate positive attitudes and the relevance of engaging patients with effective decision-making processes.
标准的阿片类药物减量往往与患者焦虑增加和疼痛评分升高有关。预先授权的隐蔽式阿片类药物减量可能会将诸如因阿片类药物减量而担心疼痛加剧等预期降至最低,并在实验环境中延长镇痛效果。我们最近观察到患者和临床医生对隐蔽式阿片类药物减量持开放态度。然而,对于他们态度背后的“原因”却知之甚少。基于这种数据缺乏的情况,我们分析了对关于患者和临床医生对慢性疼痛隐蔽式阿片类药物减量接受情况的调查问题的定性回答。74名有高剂量阿片类药物治疗史的患者和49名临床医生完成了一份基于网络的问卷,问卷中有开放式问题,考察他们对两项假设性临床试验的反应,这两项试验比较了患者预先授权的隐蔽式阿片类药物减量与标准减量。我们使用基于定性描述方法的内容分析法来分析患者和临床医生的评论。确定了五个主题:知情同意;焦虑;安全;支持;以及无知是福(或并非如此)。这些主题突出了对隐蔽式阿片类药物减量的总体积极态度。我们的研究结果强化了以患者为中心的护理的重要性,并有望从患者和临床医生的角度为临床试验的设计提供信息。这项定性研究呈现了患者和临床医生对预先授权减少阿片类药物试验的假设情景的态度。研究结果表明了积极态度以及让患者参与有效决策过程的相关性。